Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NRIX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNurix Therapeutics reports Q3 FY2026 financial results for quarter ended February 28
Filed April 8, 2026 · Period ending April 8, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release announcing financial results for the fiscal quarter ended February 28, 2026. Actual financial figures are contained in the attached press release, not in the 8-K body itself.
Item 7.01 view on EDGAR → -
low
This is a standard quarterly earnings announcement filing. The 8-K serves as a procedural wrapper for the press release (Exhibit 99.1) containing the actual financial data.
8-K: Earnings view on EDGAR →
Summary
Nurix Therapeutics filed an 8-K to announce its third quarter fiscal 2026 financial results for the period ended February 28, 2026. This is a routine quarterly earnings disclosure, with the actual financial figures, metrics, and management commentary contained in the attached press release rather than in the 8-K filing itself. The filing serves primarily as a formal SEC notification that results have been publicly released.
For retail investors, this represents a standard quarterly checkpoint to assess the company's financial health and progress. The key details—revenue, cash position, clinical trial updates, and forward guidance—would be found in the referenced press release. Investors should review that press release for specifics on cash runway, R&D spending, and any updates to the company's drug development pipeline, which are critical metrics for a clinical-stage biotech like Nurix.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 8, 2026, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended February 28, 2026.
The company disclosed its financial results for the fiscal quarter ended February 28, 2026 via press release. The 8-K itself does not contain the actual financial figures; those are in the attached press release (Exhibit 99.1). This is a standard quarterly earnings announcement filing.
Event · Item 9.01 — Financial Statements and Exhibits
Nurix filed an 8-K attaching a press release dated April 8, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
99.1 Press Release dated April 8, 2026
The 8-K references an attached press release dated April 8, 2026. The filing body itself contains no substantive disclosure about the press release content, making this a procedural filing. The actual material event, if any, would be described in Exhibit 99.1.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify